PCN236 A LANDMARK RESPONSE ANALYSIS TO DETERMINE COST-EFFECTIVENESS OF THIRD-LINE NIVOLUMAB MONOTHERAPY FOR SMALL CELL LUNG CANCER

Nov 1, 2019, 00:00 AM
10.1016/j.jval.2019.09.431
https://www.valueinhealthjournal.com/article/S1098-3015(19)32809-8/fulltext
Section Title :
Section Order : 10356
First Page :
https://www.valueinhealthjournal.com/action/showCitFormats?pii=S1098-3015(19)32809-8&doi=10.1016/j.jval.2019.09.431
HEOR Topics :
Tags :
Regions :